Potent results from a new immune treatment seen in patients with hard-to-treat blood cancers


All patients in the Phase I / II clinical trial of glofitamab had Diffuse Large B-Cell Lymphoma (DLBCL) and their cancer had relapsed or was no longer responding to conventional treatments, including CAR T-cell therapy.

How ‘Forspoken’ is trying to step out of ‘Final Fantasy’s’ shadow

Previous article

Novel wearable belt with sensors accurately monitors heart failure 24/7

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Innovations